Eupraxia Pharmaceuticals’ (EPRX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a report issued on Wednesday morning,Benzinga reports. They currently have a $11.00 price objective on the stock.

EPRX has been the subject of a number of other reports. Wall Street Zen upgraded Eupraxia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. Cantor Fitzgerald boosted their price objective on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a research note on Thursday, January 15th. Zacks Research downgraded Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 17th. William Blair began coverage on Eupraxia Pharmaceuticals in a research note on Monday, March 23rd. They set an “outperform” rating for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, Eupraxia Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Eupraxia Pharmaceuticals Stock Up 0.6%

Eupraxia Pharmaceuticals stock opened at $7.06 on Wednesday. The business has a 50-day simple moving average of $7.54 and a two-hundred day simple moving average of $7.13. The company has a market cap of $426.64 million, a P/E ratio of -6.85 and a beta of 1.55. Eupraxia Pharmaceuticals has a 52-week low of $3.67 and a 52-week high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21). Research analysts anticipate that Eupraxia Pharmaceuticals will post -0.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Ally Bridge Group NY LLC bought a new position in shares of Eupraxia Pharmaceuticals during the 3rd quarter valued at approximately $5,398,000. Guardian Partners Inc. purchased a new position in Eupraxia Pharmaceuticals in the 3rd quarter worth approximately $147,000. Ingalls & Snyder LLC lifted its holdings in Eupraxia Pharmaceuticals by 58.9% in the 3rd quarter. Ingalls & Snyder LLC now owns 59,100 shares of the company’s stock worth $349,000 after purchasing an additional 21,900 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Eupraxia Pharmaceuticals by 44.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 58,058 shares of the company’s stock worth $438,000 after purchasing an additional 17,958 shares in the last quarter. Finally, Cibc World Market Inc. lifted its holdings in Eupraxia Pharmaceuticals by 287.0% in the 4th quarter. Cibc World Market Inc. now owns 58,050 shares of the company’s stock worth $437,000 after purchasing an additional 43,050 shares in the last quarter.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.